ALK-ADC Drug: Validation of Efficacy of ALK-Targeted Humanized Antibody-Drug Conjugate with Pyrrolobenzodiazepine Payload in ALK-Expressing Cancers
On August 15, 2025, the journal Nature Communications published an article titled “A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers” (靶向间变性淋巴瘤激酶（ALK）的人源化抗体药物偶联物搭载吡咯并苯二氮䓬有效载荷在ALK表达癌症中的疗效验证).This study developed a novel ALK-targeted antibody-drug conjugate CDX0239-PBD, which demonstrates significant anti-tumor activity and survival benefits in various ALK-expressing pediatric and adult tumor models (including neuroblastoma, … Read more
